0001104659-23-126468.txt : 20231215 0001104659-23-126468.hdr.sgml : 20231215 20231215171157 ACCESSION NUMBER: 0001104659-23-126468 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231212 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 231491309 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 8-K 1 tm2333038d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2023

Eagle Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-36306	20-8179278
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ		07677
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 326-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		EGRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

The information appearing below under Item 4.02 is incorporated herein by reference.

Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

On December 12, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Eagle Pharmaceuticals, Inc. (the “Company”), based on the recommendation of, and after consultation with, the Company’s management concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements for the quarter ended June 30, 2023 (the “Non-Reliance Period”), as previously filed with the SEC, should no longer be relied upon and should be restated due to the matters described below. The Company’s management and the Audit Committee have discussed the matters disclosed in this current report on Form 8-K with Ernst & Young LLP, the Company’s independent registered public accounting firm.

As previously disclosed in the Company’s Form NT 10-Q filed on November 9, 2023 (the “NT 10-Q”), the Company, in the course of preparing its interim financial statements for the quarter ended September 30, 2023, determined that it was necessary to review potential adjustments primarily relating to reserves for PEMFEXY® returns and price adjustments estimated in the amount of $15.0 million to $20.0 million (the “Estimated Adjustment Amount”).

During its review, the Company discovered that reserves recorded in its financial statements for the quarter ended June 30, 2023 primarily relating to returns and price adjustments for PEMFEXY® did not reflect certain information that should have been considered at the time the Company prepared its financial statements for the quarter ended June 30, 2023. Had that information been considered, such reserves for the quarter ended June 30, 2023 would have increased, which would have reduced the Company’s net product sales for the quarter ended June 30, 2023 by a corresponding amount. The expected increase in reserves for the quarter ended June 30, 2023 represents a portion of the Estimated Adjustment Amount. The Company is in the process of determining which portions of the Estimated Adjustment Amount will be allocated between the quarter ended June 30, 2023 and the quarter ended September 30, 2023. The Estimated Adjustment Amount takes into account other reserve corrections in the Non-Reliance Period. At this time, the Company has not fully completed its review, and the expected financial statement impacts are preliminary and subject to change.

As a result of the foregoing, the Company has identified material weaknesses in its internal control over financial reporting that existed as of June 30, 2023 and has re-evaluated the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2023. Based on this assessment, the Company’s disclosure controls and procedures were ineffective as of June 30, 2023. The Company is continuing to evaluate its internal control over financial reporting and will report its remediation plan and further information regarding the material weaknesses in an amendment to its previously filed Form 10-Q for the quarter ended June 30, 2023.

The Company intends to file an amendment to its previously filed Form 10-Q for the quarter ended June 30, 2023, which will include restated unaudited condensed consolidated financial statements for the three and six months ended June 30, 2023. The Company is continuing to assess the Estimated Adjustment Amount and any other potential items for correction as needed. Any previously issued or filed reports, press releases, earnings releases, stockholder communications, investor presentations or other communications describing the Company’s financial statements, financial results and other related financial information covering such period and any information related to the matters described above, should no longer be relied upon. In addition, the Company previously disclosed that it expected to revise its previously disclosed full year 2023 guidance downward and accordingly, such guidance should no longer be relied upon. The Company continues to work diligently on its review and preparation of the Form 10-Q for the quarter ended September 30, 2023.

The foregoing expectations are based on preliminary unaudited financial information and subject to change in connection with the completion of the reporting process and preparation of the Company's financial statements, and actual results may vary significantly from the foregoing expectations.

In addition, under the terms of the Third Amended and Restated Credit Agreement (the “Credit Agreement”) among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), the Company was required to deliver to the Administrative Agent and lenders, by not later than November 14, 2023, quarterly financial statements certified by one of its officers as presenting fairly in all material respects the financial condition and results of operations of the Company and its consolidated subsidiaries for the fiscal quarter ended September 30, 2023 (the “September 2023 Financials”) pursuant to a covenant requiring delivery of quarterly financials within 45 days of the end of each of the first three fiscal quarters of each fiscal year. The Company failed to timely deliver the September 2023 Financials, which such failure constituted a default under the Credit Agreement, subject to a 30-day cure period ending December 14, 2023. The Company failed to timely deliver the September 2023 Financials and accordingly failed to cure such default within the 30-day cure period, which gave rise to an event of default under the Credit Agreement.

Further, in connection with the restatement of the financial statements for the quarter ended June 30, 2023 (the “June 2023 Financials”), the Company has concluded that the June 2023 Financials previously delivered to the Administrative Agent and lenders did not present fairly in all material respects the financial condition and results of operations of the Company and its consolidated subsidiaries for the reasons described above and were not prepared in accordance with generally accepted accounting principles, which gave rise to an event of default under the Credit Agreement.

During the continuance of an event of default, the Administrative Agent may, with the consent of the required lenders, and shall, at the request of the required lenders, by notice to the Company, terminate undrawn commitments, declare the loans then outstanding to be due and payable in full and/or exercise other remedies available to it, among other things. In addition, the Company’s obligations under the Credit Agreement are secured by a pledge of substantially all of the Company’s assets. If the Company is unable to pay its obligations, the Administrative Agent on behalf of the lenders could proceed to protect and enforce their rights under the Credit Agreement, including by foreclosure on the assets securing the Company’s obligations under the Credit Agreement. The foregoing would materially and adversely affect the Company’s business and financial condition.

The Company is in the process of seeking waivers of, and amendments related to, the foregoing events of default under the Credit Agreement. However, there can be no assurance that the Company will be able to obtain such waivers or amendments.

Forward-Looking Statements

This current report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “intend,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “seek,” “continue,” “estimate,” “and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to: the expected adjustments to the Company’s financial statements, including the estimated amount and impact of adjustments on the Company’s financial statements, expectations with respect to the Company’s guidance, expectations with respect to the Company’s internal control over financial reporting and disclosure controls and procedures and related remediation, the potential for additional adjustments to the Company’s financial statements, the Company’s expectations with respect to its events of default under the Credit Agreement and its ability to seek waivers or amendments related thereto, the potential actions that the Administrative Agent on behalf of the lenders could take to protect and enforce their rights under the Credit Agreement, and the expected filing of an amendment to the Company’s Form 10-Q for the quarter ended June 30, 2023 and a Form 10-Q for the quarter ended September 30, 2023. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the completion of the review and preparation of the Company’s financial statements and internal control over financial reporting and disclosure controls and procedures and the timing thereof; the discovery of additional information; further delays in the Company’s financial reporting, including as a result of unanticipated factors; the Company’s ability to obtain necessary waivers or amendments to the Credit Agreement; the possibility that the Company is unable to regain compliance with, or thereafter continue to comply with, the Nasdaq Listing Rules, or experience violations of additional Nasdaq Listing Rules; the possibility that the Nasdaq may delist the Company’s securities; the Company’s ability to remediate material weaknesses in its internal control over financial reporting; the Company’s ability to recruit and hire a new Chief Executive Officer; the impacts of the post- COVID-19 environment and geopolitical factors such as the conflicts between Russia and Ukraine and Gaza and Israel; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; the outcome of litigation; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and guidance and may cause the Company’s actual results and outcomes to materially differ from its estimates, projections and guidance; and those risks and uncertainties identified in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2023, the Company’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, and for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this current report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2023

	EAGLE PHARMACEUTICALS, INC.

	By:	/s/ Brian Cahill
		Brian Cahill
		Chief Financial Officer

EX-101.SCH 2 egrx-20231212.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 egrx-20231212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 egrx-20231212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 12, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 12, 2023
Entity File Number	001-36306
Entity Registrant Name	Eagle Pharmaceuticals, Inc.
Entity Central Index Key	0000827871
Entity Tax Identification Number	20-8179278
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	50 Tice Boulevard
Entity Address, Address Line Two	Suite 315
Entity Address, City or Town	Woodcliff Lake
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07677
City Area Code	201
Local Phone Number	326-5300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	EGRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 tm2333038d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000827871 2023-12-12 2023-12-12 iso4217:USD shares iso4217:USD shares false 0000827871 8-K 2023-12-12 Eagle Pharmaceuticals, Inc. DE 001-36306 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 201 326-5300 false false false false Common Stock, par value $0.001 per share EGRX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eagleus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports egrx-20231212.xsd egrx-20231212_lab.xml egrx-20231212_pre.xml tm2333038d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333038d1_8k.htm": { "nsprefix": "egrx", "nsuri": "http://eagleus.com/20231212", "dts": { "schema": { "local": [ "egrx-20231212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "egrx-20231212_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20231212_pre.xml" ] }, "inline": { "local": [ "tm2333038d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://eagleus.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333038d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333038d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-126468-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-126468-xbrl.zip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end